Hope for hepatitis c relapsers: new combo trial shows promise
NCT ID NCT01466192
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tested a new drug called MP-424 (telaprevir) combined with two standard medications (peginterferon and ribavirin) in 108 adults with genotype 2 hepatitis C whose infection returned after previous treatment. The goal was to see if this triple therapy could clear the virus for good. Participants took the drugs for up to 24 weeks, and the main measure was whether the virus remained undetectable 24 weeks after treatment ended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Minato-ku, Tokyo, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
What this could lead to
If successful, this could offer a more effective treatment option for people with genotype 2 hepatitis C who relapsed after previous therapy, potentially leading to higher cure rates.
What could go wrong
This is a completed phase 3 trial, but results may not apply to all patients, and the combination therapy can cause significant side effects like anemia and depression.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.